title: FDA approved drugs complexed to their targets: evaluating pose prediction accuracy of docking protocols.
abstract: Efficient drug discovery programs can be designed by utilizing existing pools of knowledge from the already approved drugs. This can be achieved in one way by repositioning of drugs approved for some indications to newer indications. Complex of drug to its target gives fundamental insight into molecular recognition and a clear understanding of putative binding site. Five popular docking protocols, Glide, Gold, FlexX, Cdocker and LigandFit have been evaluated on a dataset of 199 FDA approved drug-target complexes for their accuracy in predicting the experimental pose. Performance for all the protocols is assessed at default settings, with root mean square deviation (RMSD) between the experimental ligand pose and the docked pose of less than 2.0 Å as the success criteria in predicting the pose. Glide (38.7 %) is found to be the most accurate in top ranked pose and Cdocker (58.8 %) in top RMSD pose. Ligand flexibility is a major bottleneck in failure of docking protocols to correctly predict the pose. Resolution of the crystal structure shows an inverse relationship with the performance of docking protocol. All the protocols perform optimally when a balanced type of hydrophilic and hydrophobic interaction or dominant hydrophilic interaction exists. Overall in 16 different target classes, hydrophobic interactions dominate in the binding site and maximum success is achieved for all the docking protocols in nuclear hormone receptor class while performance for the rest of the classes varied based on individual protocol.
authors.affiliation: Molecular Modeling Group, Indian Institute of Chemical Technology, Hyderabad,, 500 607, Andhra Pradesh, India.
authors.forename: Mohammed H
authors.initials: MH
authors.lastname: Bohari
authors.forename: G Narahari
authors.initials: GN
authors.lastname: Sastry
mesh_terms: D001665:Binding Sites; D018360:Crystallography, X-Ray; D030562:Databases, Protein; D017277:Drug Approval; D006860:Hydrogen Bonding; D057927:Hydrophobic and Hydrophilic Interactions; D008024:Ligands; D062105:Molecular Docking Simulation; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D011506:Proteins / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000145:classification; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D008024:Ligands; D004364:Pharmaceutical Preparations; D011506:Proteins